The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 701–800 of 1,006
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Pourabdollah, M., Bahmanyar, M., Atenafu, E. G., Reece, D., Hou, J., & Chang, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0354-2 · Cited by 24
Combinatorial mapping of E3 ubiquitin ligases to their target substrates
Suiter, C. C., Calderon, D., Lee, D. S., Chiu, M., Jain, S., Chardon, F. M., Lee, C., Daza, R. M., Trapnell, C., Zheng, N., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.01.016 · Cited by 24
Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates
de Gialluly, M. A. S., Allen, A. R., Hayes, E. H., Zhuang, P., Goldfarb, R. B., Farrar, A. N., Federov, Y., & Adams, D. (2025) · Nature Communications · doi:10.1038/s41467-025-61818-7 · Cited by 25
Jackson, K. L., Yin, N., Agafonov, R. V., Chaturvedi, P., Cole, K. S., Eron, S. J., Good, A. C., Hart, J. A., He, M., Henderson, C. S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01317 · Cited by 25
The von Hippel–Lindau Tumor Suppressor Protein
Kaelin, W. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050527 · Cited by 24
Self-citationAmatangelo, M. D., Flynt, E., Stong, N., Ray, P. R., Oekelen, O. V., Wang, M., Ortiz, M., Maciag, P., Peluso, T., Parekh, S. S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101571 · Cited by 26
Stokes, M. E., Wenzl, K., Huang, C. C., Ortiz, M., Hsu, C.-C., Maurer, M. J., Stong, N., Nakayama, Y., Wu, L., Chiu, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50830-y · Cited by 25
Lenalidomide for the treatment of B-cell lymphoma
Garciaz, S., Coso, D., de Colella, J. S., & Bouabdallah, R. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1208170 · Cited by 25
Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance
Yang, L., Chen, J., Huang, X., Zhang, E., He, J., & Cai, Z. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.12.012 · Cited by 26
BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients
Łacina, P., Butrym, A. K., Mazur, G. J., & Bogunia‐Kubik, K. (2018) · Genes · doi:10.3390/genes9050226 · Cited by 24
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
Martinelli, S., Maffei, R., Fiorcari, S., Quadrelli, C., Zucchini, P., Benatti, S., Potenza, L., Luppi, M., & Marasca, R. (2018) · Haematologica · doi:10.3324/haematol.2017.187070 · Cited by 25
Byrd, J. C., Ruppert, A. S., Heerema, N. A., Halvorson, A. E., Hoke, E. E., Smith, M. R., Godwin, J. E., Couban, S., Fehniger, T. A., Thirman, M. J., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015396 · Cited by 26
Molecular biology of human T cell leukemia virus
Ratner, L. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.003 · Cited by 25
Targeted protein degradation in antibacterial drug discovery?
Gopal, P., & Dick, T. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.005 · Cited by 24
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201611281 · Cited by 24
Self-citationCellular parameters shaping pathways of targeted protein degradation
Cardno, A., Kennedy, B., & Lindon, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08104-w · Cited by 24
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting
Buettner, R., Morales, C. J., Caserta, E., Troadec, E., Gunes, E. G., Viola, D., Khalife, J., Li, H., Keats, J. J., Christofferson, A. W., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027227 · Cited by 23
Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 23
Zhang, S., Chen, Y., Xu, Z., Yang, J., Sun, R., Wang, J., Sun, Y., Jiang, B., Yang, X., & Tan, W. (2022) · Theranostics · doi:10.7150/thno.75421 · Cited by 24
Gonthier, K., Weidmann, C., Berthiaume, L., Jobin, C., Lacouture, A., Lafront, C., Harvey, M., Neveu, B., Loehr, J., Bergeron, A., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13441 · Cited by 26
Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Ismail, T. M., Crick, R. G., Du, M., Shivkumar, U., Carnell, A. J., Barraclough, R., Wang, G., Cheng, Z., Yu, W., Platt-Higgins, A. M., et al. (2023) · Biomolecules · doi:10.3390/biom13071099 · Cited by 24
Chong, P. S. Y., Chooi, J.-Y., Lim, J. S. L., Leow, A. C. Y., Toh, S. H. M., Azaman, I., Koh, M. Y., Teoh, P. J., Tan, T. Z., Chung, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3481 · Cited by 23
Hartley-Brown, M. A., Mo, C. C., Nadeem, O., Midha, S., Laubach, J. P., & Richardson, P. G. G. (2024) · Cancers · doi:10.3390/cancers16061166 · Cited by 25
Crbn-based molecular Glues: Breakthroughs and perspectives
An, J., & Zhang, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117683 · Cited by 25
Nutt, M. J., & Stewart, S. G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104010 · Cited by 24
Differential effects of lenalidomide during plasma cell differentiation
Jourdan, M., Cren, M., Schafer, P. H., Robert, N., Duperray, C., Vincent, L., Céballos, P., Cartron, G., Rossi, J., Moreaux, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8581 · Cited by 23
Tang, S., Ma, D., Cheng, B., Fang, Q., Kuang, X., Yu, K., Wang, W., Hu, B., & Wang, J. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.005 · Cited by 23
Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
Nahas, M. R., Rosenblatt, J. M., Lazarus, H. M., & Avigan, D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.002 · Cited by 23
CSNAP, the smallest CSN subunit, modulates proteostasis through cullin-RING ubiquitin ligases
Füzesi-Levi, M. G., Fainer, I., Enchev, R. I., Ben‐Nissan, G., Levin, Y., Kupervaser, M., Friedlander, G., Salame, T. M., Nevo, R., Peter, M., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0392-8 · Cited by 24
Jeng, C., Fu, S.-J., You, C.-Y., Peng, Y.-J., Hsiao, C.-T., Chen, T., & Tang, C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00076 · Cited by 25
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Zaman, S. U., Pagare, P. P., Huang, B., Rilee, G. J., Ma, Z., Zhang, Y., & Li, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107613 · Cited by 22
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Jin, Y., & Lee, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400267 · Cited by 22
Development of Potent and Selective CK1α Molecular Glue Degraders
Geng, Q., Jiang, Z., Byun, W. S., Donovan, K. A., Zhuang, Z., Jiang, F., Jones, H. M., Razumkov, H., Tang, M. T., Sarott, R. C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02415 · Cited by 22
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 22
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 23
Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 23
Targeted Therapies for Multiple Myeloma
Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 23
Bohl, S., Schmalbrock, L. K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., Blätte, T. J., Knödler, S., Röhner, L., Miller, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003541 · Cited by 22
Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
Allegra, A., Petrarca, C., Gioacchino, M. D., Casciaro, M., Musolino, C., & Gangemi, S. (2022) · Antioxidants · doi:10.3390/antiox11030455 · Cited by 22
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 23
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
Jiang, W., Jiang, Y., Luo, Y., Qiao, W., & Yang, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115950 · Cited by 24
IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease
Liu, Q., Zheng, Y., Sturmlechner, I., Jain, A. K., Own, M., Yang, Q., Zhang, H., Vairo, F. P. E., Cerosaletti, K. M., Buckner, J. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178692 · Cited by 22
Trial Watch: Proteasomal inhibitors for anticancer therapy
Obrist, F., Manic, G., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.974463 · Cited by 23
Browning, R. L., Byrd, W. H., Gupta, N., Jones, J. A., Mo, X. M., Hertlein, E. K., Yu, L., Muthusamy, N., & Byrd, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0291 · Cited by 22
Reddy, N. M., & Thiéblemont, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx358 · Cited by 22
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade
Zheng, J. J., Sha, Y., Roof, L., Foreman, O., Lazarchick, J. J., Venkata, J. K., Kozlowski, C., Gasparetto, C., Chao, N. J. A., Ebens, A. J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.003 · Cited by 22
IKZF3/Aiolos Is Associated with but Not Sufficient for the Expression of IL-10 by CD4+ T Cells
Ridley, M. L., Fleskens, V., Roberts, C. A., Lalnunhlimi, S., Alnesf, A., O’Byrne, A. M., Steel, K. J. A., Povoleri, G. A. M., Sumner, J., Lavender, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901283 · Cited by 22
Sweeney, M. A., Iakova, P. A., Maneix, L., Shih, F.-Y., Cho, H. E., Sahin, E., & Catic, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70610-0 · Cited by 22
Lin, W., Li, Y., Min, J., Liu, J., Yang, L., Lee, R. E., Jr., & Chen, T. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00507 · Cited by 22
Structure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 24
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Yan, Y., Shao, J., Ding, D., Pan, Y., Tran, P., Yan, W., Wang, Z., Li, H., & Huang, H. (2022) · Chemical Communications · doi:10.1039/d1cc06525d · Cited by 22
Quwaider, D., Corchete, L. A., Martín‐Izquierdo, M., Hernández-Sánchez, J. M., Rojas, E. A., Cardona‐Benavides, I. J., García‐Sánz, R., Herrero, A. B., & Gutierrez, N. C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00271-4 · Cited by 22
Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells
Bristol, J. A., Brand, J., Ohashi, M., Eichelberg, M. R., Casco, A., Nelson, S. E., Hayes, M., Romero-Masters, J. C., Baiu, D. C., Gumperz, J. E., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010453 · Cited by 22
Zhou, L., & Xu, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1317-7 · Cited by 23
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 23
Chemogenetic Minitool for Dissecting the Roles of Protein Phase Separation
Chung, C.-I., Yang, J., & Shu, X. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00251 · Cited by 21
Chang, X., Qu, F., Li, C., Zhang, J., Zhang, Y., Xie, Y., Fan, Z., Bian, J., Wang, J., Li, Z., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22024 · Cited by 22
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment
Butrym, A. K., Rybka, J., Łacina, P., Gębura, K., Frontkiewicz, D., Bogunia‐Kubik, K., & Mazur, G. J. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.007 · Cited by 23
Jia, X., Pan, L., Zhu, M., Hu, H., Zhai, L., Liu, J., Hu, M., Liu, B., & Tan, M. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103545 · Cited by 21
Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
Stefka, A. T., Johnson, D. C., Rosebeck, S., Park, J., Nakamura, Y., & Jakubowiak, A. J. (2019) · Cancer Medicine · doi:10.1002/cam4.2695 · Cited by 22
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 22
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen
Mo, Z., Wood, S., Namiranian, S., Mizukoshi, R., Weng, S., Jang, I. S., Fontanillo, C., Baughman, J. M., Silva-Torres, A., Slade, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003431 · Cited by 21
Self-citationA Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins
Gama-Brambila, R. A., Chen, J., Dabiri, Y., Tascher, G., Němec, V., Münch, C., Song, G., Knapp, S., & Cheng, X. (2021) · JACS Au · doi:10.1021/jacsau.1c00007 · Cited by 23
SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
Du, L., Liu, W., Pichiorri, F., & Rosen, S. T. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00450-9 · Cited by 21
SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics
Sialana, F. J., Roumeliotis, T. I., Bouguenina, H., Hak, L. C. W., Wang, H., Caldwell, J., Collins, I., Chopra, R., & Choudhary, J. S. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00092 · Cited by 21
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2
Zhu, Y. X., Yin, H. H., Bruins, L. A., Shi, C.-X., Jedlowski, P. M., Aziz, M., Sereduk, C., Kortuem, K. M., Schmidt, J. E., Champion, M. D., et al. (2014) · Blood · doi:10.1182/blood-2014-05-577130 · Cited by 21
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
Barley, K. M., He, W., Agarwal, S., Jagannath, S., & Chari, A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1151507 · Cited by 21
Potential of NK cells in multiple Myeloma therapy
Khan, A., Devarakonda, S. S., Bumma, N., Chaudhry, M., & Benson, D. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1617128 · Cited by 21
Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma
Talley, P., Chantry, A., & Buckle, C. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldu041 · Cited by 23
Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
Parker, G. S., Toth, J. I., Fish, S., Blanco, G., Kampert, T., Li, X., Yang, L., Stumpf, C. R., Steadman, K., Jamborcic, A., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0219 · Cited by 23
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Chen, J., Jin, J., Gu, W., Zhao, Z., Hu, Y., Zhou, Y., Nagle, D. G., Xi, Q., Zhang, X., Sun, Q., et al. (2023) · Cancer Science · doi:10.1111/cas.15733 · Cited by 21
A Degron Blocking Strategy Towards Improved CRL4 CRBN Recruiting PROTAC Selectivity**
Bouguenina, H., Scarpino, A., O’Hanlon, J. A., Warne, J. M., Wang, H., Hak, L. C. W., Sadok, A., McAndrew, C., Stubbs, M., Pierrat, O. A., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300351 · Cited by 27
IKAROS: from chromatin organization to transcriptional elongation control
Affar, M., Bottardi, S., Quansah, N., Lemarié, M., Ramòn, A. C., Affar, E. B., & Milot, É. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01212-2 · Cited by 22
Bhowmick, K., Suskil, M. V., Al‐Odat, O. S., Elbezanti, W. O., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33091 · Cited by 21
Salvage Therapy of Multiple Myeloma: The New Generation Drugs
Romano, A., Conticello, C., Cavalli, M. M., Vetro, C., Raimondo, C. D., Martina, V., Schinocca, E., Fauci, A. L., Parrinello, N. L., Chiarenza, A., et al. (2014) · BioMed Research International · doi:10.1155/2014/456037 · Cited by 21
Bat‐Erdene, A., Miki, H., Oda, A., Nakamura, S., Teramachi, J., Amachi, R., Tenshin, H., Hiasa, M., Iwasa, M., Harada, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12594 · Cited by 20
Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner
Zhou, L., Hao, Z., Wang, G., & Xu, G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx433 · Cited by 20
Recent advances in target identification of bioactive natural products
Yoshida, M. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1533804 · Cited by 21
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Lindner, S., Steinebach, C., Kehm, H., Mangold, M., Gütschow, M., & Krönke, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59472 · Cited by 16
Li, S., Fu, J., Yang, J., Ma, H., Bhutani, D., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2020) · Blood · doi:10.1182/blood.2020006334 · Cited by 22
Garber, K. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02164-9 · Cited by 22
Ramón-Vázquez, A., Flood, P. F., Cashman, T. L., Patil, P., & Ghosh, S. K. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103735 · Cited by 20
Pan, Y., Wang, Y., & Gou, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108491 · Cited by 19
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation
Slabicki, M. M., Park, J., Nowak, R. P., Burman, S. S. R., Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.019 · Cited by 20
Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., van Velzen, J. F., Emmelot, M. E., van Kessel, B., Levin, M., Bos, G. M. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26131 · Cited by 21
Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances
Chihara, D., & Dunleavy, K. M. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.10.015 · Cited by 19
Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 21
HiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degrader Development
Tsang, T., Huerta, F., Liu, Y., Che, J., Metivier, R. J., Ferrao, S., Donovan, K. A., Jones, L. H., Zerfas, B. L., & Nowak, R. P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00084 · Cited by 19
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 21
Molecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 19
PCMT1 generates the C-terminal cyclic imide degron on CRBN substrates
Zhao, Z., Xu, W., Feng, E. Y., Cao, S., Hermoso-López, A., Peña-Vega, P., Lloyd, H. C., Porter, A. K. D., Guzmán, M., Zheng, N., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02106-9 · Cited by 20
Heo, M. H., Park, H. Y., Ko, Y. H., Kim, W. S., & Kim, S. J. (2017) · Journal of Cancer · doi:10.7150/jca.17358 · Cited by 19
Novel therapeutic agents for relapsed classical Hodgkin lymphoma
von Keudell, G., & Younes, A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15695 · Cited by 19
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 20
Hypnotic effect of thalidomide is independent of teratogenic ubiquitin/proteasome pathway
Hirose, Y., Kitazono, T., Sezaki, M., Abe, M., Sakimura, K., Funato, H., Handa, H., Vogt, K. E., & Yanagisawa, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917701117 · Cited by 19
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.